BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year book value per share growth
| Period | Value |
|---|---|
| Q4 2025 | 69.40% |
| Q3 2025 | 8.28% |
| Q2 2025 | 7.00% |
| Q1 2025 | 5.73% |
| Q4 2024 | -1.34% |
| Q3 2024 | 1.71% |
| Q2 2024 | 0.29% |
| Q1 2024 | -2.17% |
| Q4 2023 | -4.36% |
| Q3 2023 | -5.44% |
| Q2 2023 | -18.03% |
| Q1 2023 | -10.50% |
| Q4 2022 | -20.92% |
| Q3 2022 | -12.43% |
| Q2 2022 | -30.53% |
| Q1 2022 | -50.96% |
| Q4 2021 | 28.34% |
| Q3 2021 | -37.86% |
| Q2 2021 | -40.83% |
| Q1 2021 | -287.71% |
| Q4 2020 | -157.23% |
| Q3 2020 | -59.76% |
| Q2 2020 | 1901.01% |
| Q1 2020 | -91.88% |
| Q4 2019 | 177.98% |
| Q3 2019 | -348.43% |
| Q2 2019 | -140.78% |
| Q1 2019 | -54.44% |
| Q4 2018 | -35.14% |
| Q3 2018 | 47.87% |
| Q2 2018 | -25.72% |
| Q1 2018 | -26.06% |
| Q4 2017 | -29.31% |
| Q3 2017 | 302.21% |
| Q2 2017 | -41.59% |
| Q1 2017 | 2296.12% |
| Q4 2016 | -60.50% |
| Q3 2016 | -70.19% |
| Q2 2016 | -51.90% |
| Q1 2016 | -41.96% |